Company Nymox Pharmaceutical Corporation
Equities
NYMXF
BSP733981026
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2 USD | +11.11% |
|
-2.44% | -66.10% |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Averback
CEO | Chief Executive Officer | 73 | 95-05-29 |
Patrick Doody
BRD | Director/Board Member | - | 23-07-11 |
Director/Board Member | - | 23-03-20 | |
Suresh Kalbag
PRN | Corporate Officer/Principal | - | - |
General Counsel | - | 20-02-05 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David S. Morse
BRD | Director/Board Member | 67 | 06-06-07 |
Paul Averback
CEO | Chief Executive Officer | 73 | 95-05-29 |
Director/Board Member | 88 | 15-06-30 | |
Director/Board Member | - | 23-03-20 | |
Patrick Doody
BRD | Director/Board Member | - | 23-07-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 93,265,000 | 54,049,529 ( 57.95 %) | 0 | 57.95 % |
Company contact information
![address Nymox Pharmaceutical Corporation(NYMXF)](https://cdn.zonebourse.com/static/address/25054783.png)
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
-66.10% | 18.67M | |
+16.59% | 44.44B | |
+42.61% | 40.03B | |
-10.62% | 37.68B | |
+29.92% | 31.46B | |
-9.23% | 27.29B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |
- Stock Market
- Equities
- NYMXF Stock
- Company Nymox Pharmaceutical Corporation